We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioactive Milk Peptides and Blood Pressure

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01031485
First Posted: December 14, 2009
Last Update Posted: December 23, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Helsinki University
Information provided by:
Valio Ltd
  Purpose
The purpose of this study is to investigate the effects of bioactive milk peptides on blood pressure in mildly hypertensive subjects.

Condition Intervention Phase
Stage 1 Hypertension Dietary Supplement: Milk peptides and plant sterols Other: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Further study details as provided by Valio Ltd:

Primary Outcome Measures:
  • Blood pressure

Study Start Date: January 2010
Study Completion Date: August 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Spread with milk peptides and plant sterols Dietary Supplement: Milk peptides and plant sterols
Placebo Comparator: Standard spread Other: Placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • age 30-60 years
  • systolic blood pressure 140-160 mmHg and diastolic blood pressure 90-99 mmHg in office measurement
  • apparently healthy

Exclusion Criteria:

  • antihypertensive and lipid-lowering drugs
  • unstable coronary artery disease, diabetes, malignant diseases, secondary hypertension
  • BMI > 32 kg/m2
  • milk allergy
  • smoking
  • alcohol abuse
  • pregnancy, lactation
  • simultaneous participation in other clinical trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01031485


Locations
Finland
Valio Ltd
Helsinki, Uusimaa, Finland, 00370
Sponsors and Collaborators
Valio Ltd
Helsinki University
  More Information

ClinicalTrials.gov Identifier: NCT01031485     History of Changes
Other Study ID Numbers: Valio-70
First Submitted: December 11, 2009
First Posted: December 14, 2009
Last Update Posted: December 23, 2014
Last Verified: December 2009

Keywords provided by Valio Ltd:
hypertension
blood pressure
milk peptides
bioactive peptides
randomized controlled trial

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases


To Top